Regan Sherman leads our engagement with patient communities around the world.
As a former advocate herself, Regan seeks to understand and elevate the needs of people living with orphan diseases to guide our efforts throughout the drug development process, from clinical trial design through to access.
"Our team is grounded in the belief that people living with rare and orphan conditions and their families are disease experts and key stakeholders in the development of new therapies. We are grateful for more than 10 years of collaboration with the Niemann-Pick community that has helped bring us to our first regulatory submission. Support and guidance from patient communities in all of the disease areas we're involved with are critical to our continued success."